Literature DB >> 1313067

Prevention of human rotavirus-induced diarrhea in gnotobiotic piglets using bovine antibody.

J P Schaller1, L J Saif, C T Cordle, E Candler, T R Winship, K L Smith.   

Abstract

The efficacy of passively administered bovine antibody for preventing human rotavirus (HRV)-induced diarrhea was investigated using a gnotobiotic pig model. Cows were immunized with inactivated HRV serotypes 1 (Wa) and 2 (S2) and simian rotavirus serotype 3 (SA11), and immune colostrum and milk were collected. Antibody concentrates derived from these materials were fed to germ-free piglets that were subsequently inoculated with HRV Wa. Both viral shedding and diarrhea were effectively reduced or eliminated in a dose-dependent manner as a result of HRV immune antibody feeding. A quantitative virus-neutralizing (VN) antibody method permitted assessment of the functional antibody dose required to achieve a 50% reduction of disease (PD50). PD50 dose levels of 15.8 and 19.5 x 10(6) VN antibody units were determined for inhibition of diarrhea and viral shedding, respectively. Studies reported here provide new information on the quantitative relationship between protective antibody dose and diarrheal disease response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313067      PMCID: PMC7110050          DOI: 10.1093/infdis/165.4.623

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja saponaria Molina.

Authors:  Ka Ian Tam; Michael R Roner
Journal:  Antiviral Res       Date:  2011-04-23       Impact factor: 5.970

3.  Early adaptive immune responses in the respiratory tract of foot-and-mouth disease virus-infected cattle.

Authors:  J Pega; D Bucafusco; S Di Giacomo; J M Schammas; D Malacari; A V Capozzo; J Arzt; C Pérez-Beascoechea; E Maradei; L L Rodríguez; M V Borca; M Pérez-Filgueira
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

4.  Antibody-secreting cell responses to rotavirus proteins in gnotobiotic pigs inoculated with attenuated or virulent human rotavirus.

Authors:  K O Chang; O H Vandal; L Yuan; D C Hodgins; L J Saif
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

5.  Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease.

Authors:  L Yuan; L A Ward; B I Rosen; T L To; L J Saif
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Development of mucosal and systemic lymphoproliferative responses and protective immunity to human group A rotaviruses in a gnotobiotic pig model.

Authors:  L A Ward; L Yuan; B I Rosen; T L Tô; L J Saif
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

Review 7.  Rotavirus vaccines: an overview.

Authors:  K Midthun; A Z Kapikian
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

8.  Effects of maternal antibodies on protection and development of antibody responses to human rotavirus in gnotobiotic pigs.

Authors:  D C Hodgins; S Y Kang; L deArriba; V Parreño; L A Ward; L Yuan; T To; L J Saif
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Development of a human rotavirus induced diarrhea model in Chinese mini-pigs.

Authors:  Jin-Tao Li; Jing Wei; Hong-Xia Guo; Jiang-Bo Han; Nan Ye; Hai-Yang He; Tian-Tian Yu; Yu-Zhang Wu
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

10.  Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.

Authors:  L Yuan; C Iosef; M S Azevedo; Y Kim; Y Qian; A Geyer; T V Nguyen; K O Chang; L J Saif
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.